Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 115,935

Document Document Title
WO/2023/220715A1
The present disclosure relates to compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutica...  
WO/2023/219456A1
The present invention relates to a quinoline derivative, a preparation method therefor, and a pharmaceutical composition including same as an active ingredient for the prevention or treatment of cancer, autoimmune diseases, fibrosis, and...  
WO/2023/214317A1
Provided herein a method for treating or preventing a protein misfolding and deposition disease in a subject, by administering to the subject a low dose amount of compound (1). Provided herein is also a method for reversing or preventing...  
WO/2023/215277A1
The present disclosure relates to trimeprazine for use in methods of treating trigeminal neuralgia and pain related thereto, by administering to a patient in need thereof a therapeutically effective amount of trimeprazine. The methods ma...  
WO/2018/228692A9
The invention provides Cav2.3 R-type voltage gated calcium channel (coded by the CACNA1E gene) antagonists for the treatment and for use in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and pharmaceutica...  
WO/2023/213850A1
The present invention relates to a compound and pharmaceutical compositions thereof for use in preventing or treating a tauopathy.  
WO/2023/214833A1
The present invention relates to a fusion protein comprising GLP-1, immunoglobulin Fc, and IGF-1, and use thereof. The fusion protein of the present invention has excellent efficiency in blood-brain barrier permeability, and thus can be ...  
WO/2023/215133A1
The present invention relates to compounds of formula (I) useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PlKfyve) as well as their use for treating diseases and disorders associated with PlKfyve.  
WO/2023/215266A1
BAG3 protein is used in the treatment of, for example, is Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Huntington disease, Lewy body disease, vascular dementia, mixed dementia and Traumatic Brain Injury, for e...  
WO/2023/214285A1
The disclosure presented herein provides methods for treating a subject suffering from a pathological condition. The method is based on a fast desensitization protocol comprising intradermal injection of female sexual hormones. Further d...  
WO/2023/213198A1
The present invention provides the following compound (I) or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, or metabolite thereof, and a pharmaceutical composition containing the compound of the present inventio...  
WO/2023/214838A1
The present invention relates to novel isoquinoline derivatives. The derivatives have an effect of promoting mitophagy activity, thereby reducing mitochondria with structural and/or functional damage. In particular, the novel isoquinolin...  
WO/2023/212811A1
This disclosure relates to heterocyclic compounds of Formula (I). As contemplated herein, heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorder...  
WO/2023/215377A1
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including neuroinflammatory diseases.  
WO/2023/213902A1
The invention relates to remofuscin for use against aging, lysomal dysfunction, for use in stimulating the expression of lysosomal lipase genes and/or lysosomal lipid chaperone genes, and for use in increasing the expression levels of th...  
WO/2023/215443A1
Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.  
WO/2023/214778A1
The present invention relates to: a pharmaceutical composition for preventing or treating degenerative brain disease, comprising at least one of an anti-CD300c antibody and an antigen-binding fragment thereof; a method for preventing or ...  
WO/2023/214189A1
Inventors have shown evidence of VEGF accumulation in extracellular Aβ plaques in the post-mortem brain of patients with Alzheimer's disease (AD) and of the APP/PS1 mouse model of AD. They identified specific binding domains involved in...  
WO/2023/215787A1
Provided are anti-syndecan-2 antibodies or antigen binding fragments thereof, as well as compositions comprising said antibody or antigen binding fragment thereof and methods useful for treating diseases associated with syndecan-2 mediat...  
WO/2023/215342A1
As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin. The present disclosure also features methods for treating or preventing trigeminal neuralgia, symptoms thereof, and/or tri...  
WO/2023/213264A1
The present invention relates to a novel oleanamide derivative for activating a KEAP/NRF2/ARE signaling pathway. The compound of the present invention is represented by general formula (I), wherein L, R3, R4, Z, and n are set forth in th...  
WO/2023/213739A1
Compounds of general formula (I), pharmaceutical compositions comprising the compound, uses of the compositions, and methods of manufacturing the compound are disclosed. The compounds are nicotinic acetylcholine receptor (nAChR) ligands,...  
WO/2023/213740A1
FTR3159/PCT (P/85142.WO01) - 74 - NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS Abstract Compounds of general formula (I), pharmaceutical compositions comprising the compound, uses of the compositions, and methods of manufacturing the compoun...  
WO/2023/213279A1
Provided in the present invention are a piperidine derivative, a preparation method therefor, and a use thereof, relating to the chemical and pharmaceutical technical fields. The piperidine derivative is a compound represented by formula...  
WO/2023/215467A1
Provided herein are compositions and methods of delivering nucleic acids, such as therapeutic mRNAs and DNA, to the central nervous system by delivery, e.g., intrathecally or intracerebrally, of nucleic acid containing lipid nanoparticle...  
WO/2023/214836A1
The present invention relates to a novel berberine analogue CD1-410. It has been identified that the novel berberine analogue promotes the activity of mitophagy, and thus can reduce mitochondria with a damaged structure and/or function. ...  
WO/2023/213854A1
Described herein is new crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1- (pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylat e.  
WO/2023/215595A1
The present disclosure is directed to methods of effectively treating or preventing anxiety disorders, e.g., social anxiety disorder, with pharmaceutical compositions comprising at least one cannabinoid, as well as methods of making and ...  
WO/2023/215697A1
Multispecific binding molecules having a first binding domain targeting a blood brain barrier target and a second binding domain targeting a neuron target, astrocyte target and / or glial cell target, and uses thereof in aiding the treat...  
WO/2023/214404A1
A mucoadhesive composition and method for the administration of the pharmaceutically effective agents is provided. Specifically, a mucoadhesive composition, composed of a mucoadhesive polymer and a plurality of active agents having diffe...  
WO/2023/214391A1
Compositions and methods for treating a cancer or a neurological disease. A method of treating a cancer or a neurological disease comprising administering to a subject in need thereof an effective amount of quercetin, vitamin B3, vitamin...  
WO/2023/214119A1
The present disclosure relates to compounds of formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, wherein R1 to R9 are as defined in the claims. Further is disclosed compounds of formula (I) for use in the treat...  
WO/2023/215376A1
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including neuropathies.  
WO/2023/214091A1
The present invention relates to use of biopterin compounds such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or 4-Amino-(6R,S)-7,8-dihydro-L-biopterin for treating a human patient suffering from a disease condition or disorder that ...  
WO/2023/215338A1
As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin. The present disclosure also features methods for treating or preventing cluster headache, symptoms thereof, and/or cluster...  
WO/2023/215455A1
The present application relates to a composition suitable for treating glial-mediated neurodegenerative disease or glial-mediated neuropsychiatric disease comprising a population of isolated human microglial progenitor cells derived from...  
WO/2023/214772A1
The present invention relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory a...  
WO/2023/214172A1
The present invention relates to crystalline forms of 6-hydroxy cannabidivarin (6-OH CBDV), methods for their production, and their use in therapy. The crystalline forms are easier to handle than other solid forms, such as glass amorphou...  
WO/2023/213836A1
The present invention discloses compounds according to Formula (I) wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compos...  
WO/2023/214282A1
Provided is a composition comprising at least one terpene for use in modulation of a physiological function via at least one selected from the group consisting of agonism of a cannabinoid type 1 receptor (CB1R), modulation of agonism of ...  
WO/2023/210811A1
An oral composition comprising: an inorganic porous material having an average particle size of 60 μm or more, as a base material; and nicotine, wherein, in the inorganic porous material, the pore volume of pores having a pore size not ...  
WO/2023/207730A1
Disclosed in the present application is an R-ketamine liquid preparation. The R-ketamine liquid preparation is an aqueous solution preparation, and comprises R-ketamine or a pharmaceutically acceptable salt thereof, a pharmaceutically ac...  
WO/2023/210233A1
The present invention addresses the problem of providing a technique for effectively exerting the activity of a polynucleotide in the brain. The problem is solved by a compound represented by general formula (1) [In the formula, Ms repre...  
WO/2023/211779A1
The present invention relates to a method for treating or preventing headache disorders selected from the group consisting of migraine, medication overuse headache, cluster headache, general headache, trigeminal neuralgia, and orofacial ...  
WO/2023/212531A1
The disclosure relates to methods of nerve repair utilizing polyethylene glycol (PEG) to fuse severed axons after injury. This approach does not depend upon the natural regeneration of injured nerves and thus can be applied to spinal cor...  
WO/2023/210405A1
This variant neurodegenerative disease-associated protein comprises an amino acid sequence in which one or several amino acids present in a region of interaction between two protofilaments (PF) among the amino acid sequences of the neuro...  
WO/2023/210767A1
Provided is a new technology for a chemical ligation reaction of oligonucleotides. When 2'-fluoro-5'-amino-nucleic acid (2F-5N nucleic acid) having a fluorine atom at the 2'-positon of 5'-amino-nucleic acid (5N nucleic acid) is synthesiz...  
WO/2023/208865A1
There is disclosed a compound of Formula (II), a method of manufacturing thereof as well as uses thereof.  
WO/2023/211684A2
A method for the prevention and/or treatment of post-operative cognitive dysfunction, which entails administering to a human or other mammal an effective amount of one or more compounds selected from the group consisting of N-substituted...  
WO/2023/210481A1
A composition for treating or preventing respiratory diseases, a composition for improving sleep or promoting sleep onset, a composition for reducing fatigue, a composition for improving complexion, a composition for improving skin textu...  

Matches 701 - 750 out of 115,935